Valuation: IXICO plc

Market Cap 1.85Cr 2.47Cr 2.17Cr 2.02Cr 3.48Cr 238.13Cr 3.54Cr 24Cr 9.37Cr 117.07Cr 9.28Cr 9.08Cr 404.79Cr P/E 2026 *
-6.07x
P/E 2027 * -6.54x
Enterprise Value 83.34L 1.11Cr 97.66L 90.82L 1.57Cr 107.08Cr 1.59Cr 11Cr 4.21Cr 53Cr 4.17Cr 4.08Cr 182.02Cr EV / Sales 2026 *
1.04x
EV / Sales 2027 * 1.38x
Free-Float
89.22%
Yield 2026 *
-
Yield 2027 * -
3 years 0.07
Extreme 0.07
0.15
5 years 0
Extreme 0.003
1.09
10 years 0
Extreme 0.003
1.47
Manager TitleAgeSince
Chief Executive Officer 53 19/08/2024
Director of Finance/CFO 50 21/08/2019
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Chairman 51 -
Director/Board Member 50 21/08/2019
Director/Board Member 60 21/01/2022
Change 5-day change 1-year change 3-year change Capi.($)
-53.33%-.--% - - 2.47Cr
+1.07%-3.49%-3.35%+11.75% 4.69TCr
+0.25%+1.65%+399.22%+647.65% 4.02TCr
-0.27%+4.45%+11.81%+60.81% 3.62TCr
+0.35%+0.87%+4.46%-10.31% 3.47TCr
+3.14%+1.02%+4.76%+43.00% 2.79TCr
-0.73%+11.84%+34.39%+134.44% 1.68TCr
+0.47%-2.74% - - 1.67TCr
+0.42%-5.52%-3.43%+9.10% 1.31TCr
-2.68%-2.49%-11.36%-34.51% 1.27TCr
Average -5.13%+0.83%+54.56%+107.74% 2.73TCr
Weighted average by Cap. +0.47%+0.91%+74.42%+138.21%

Financials

2026 *2027 *
Net sales 80L 1.07Cr 93.75L 87.18L 1.5Cr 102.79Cr 1.53Cr 10Cr 4.04Cr 51Cr 4.01Cr 3.92Cr 174.72Cr 90L 1.2Cr 1.05Cr 98.08L 1.69Cr 115.64Cr 1.72Cr 12Cr 4.55Cr 57Cr 4.51Cr 4.41Cr 196.56Cr
Net income -21.43L -28.59L -25.11L -23.35L -40.27L -28Cr -40.89L -2.77Cr -1.08Cr -14Cr -1.07Cr -1.05Cr -47Cr -28.01L -37.37L -32.82L -30.52L -52.63L -36Cr -53.44L -3.62Cr -1.42Cr -18Cr -1.4Cr -1.37Cr -61Cr
Net Debt -1.02Cr -1.36Cr -1.2Cr -1.11Cr -1.92Cr -131.05Cr -1.95Cr -13Cr -5.16Cr -64Cr -5.11Cr -5Cr -222.77Cr -61L -81.39L -71.48L -66.48L -1.15Cr -78Cr -1.16Cr -7.89Cr -3.08Cr -39Cr -3.06Cr -2.99Cr -133.22Cr
Logo IXICO plc
IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.
Employees
79
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0850GBP
Average target price
0.2600GBP
Spread / Average Target
+205.88%

Annual profits - Rate of surprise